TY - JOUR
T1 - FK-463 Fujisawa Pharmaceutical Co Ltd
AU - Groll, A. H.
AU - Walsh, T. J.
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - Novel cyclohexapeptides, pharmaceutically acceptable salts thereof, a process for preparing them and their use for the treatment of microbial infections, especially fungal infections including Pneumocystis carinii infection are claimed. The compounds are slated to be β-1,3-glucan synthase inhibitors and possess antimicrobial and antifungal activities. The in vitro antimicrobial activity was assessed against Candida albicans F6-633. The specified compound showed a MIC value of 0.1 μg/ml. Four schemes and 32 examples detail the syntheses of the compounds. Characterization is by 1H-NMR, MS and elemental analysis data. 119 Intermediates are also exemplified and characterized by 1-NMR and MS data. No compounds are specifically claimed. The specified compound is, des(N-10,12-dimethyltetradecanoyl)-N-(4-[2-(4-butoxyphenyl)-1,3,4-thiadiazol-5-y l]benzoyl)-4-[6-(3-hy droxy-4-methylproline)-4-(3-sulfooxy-4-hydroxyphenyl)-4-hydroxythreonine]pneumoc andin BO with unspecified stereochemistry.
AB - Novel cyclohexapeptides, pharmaceutically acceptable salts thereof, a process for preparing them and their use for the treatment of microbial infections, especially fungal infections including Pneumocystis carinii infection are claimed. The compounds are slated to be β-1,3-glucan synthase inhibitors and possess antimicrobial and antifungal activities. The in vitro antimicrobial activity was assessed against Candida albicans F6-633. The specified compound showed a MIC value of 0.1 μg/ml. Four schemes and 32 examples detail the syntheses of the compounds. Characterization is by 1H-NMR, MS and elemental analysis data. 119 Intermediates are also exemplified and characterized by 1-NMR and MS data. No compounds are specifically claimed. The specified compound is, des(N-10,12-dimethyltetradecanoyl)-N-(4-[2-(4-butoxyphenyl)-1,3,4-thiadiazol-5-y l]benzoyl)-4-[6-(3-hy droxy-4-methylproline)-4-(3-sulfooxy-4-hydroxyphenyl)-4-hydroxythreonine]pneumoc andin BO with unspecified stereochemistry.
UR - http://www.scopus.com/inward/record.url?scp=0033866603&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033866603&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:0033866603
VL - 2
SP - 405
EP - 412
JO - Current Opinion in Anti-infective Investigational Drugs
JF - Current Opinion in Anti-infective Investigational Drugs
SN - 1464-8458
IS - 4
ER -